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Abstract
Antimicrobial peptides coupled to a ligand, receptor or antibody for a specific pathogenic bacteria
could be used to develop narrow-spectrum pharmaceuticals with ‘targeted’ antimicrobial activity
void of adverse reactions often associated with the use of broad-spectrum antibiotics. To assess the
feasibility of this approach, in this study sheep myeloid antimicrobial peptide (SMAP) 28 was
linked to affinity- and protein G-purified rabbit immunoglobulin G (IgG) antibodies specific to the
outer surface of Porphyromonas gingivalis strain 381. The selective activity of the P. gingivalis
IgG–SMAP28 conjugate was then assessed by adding it to an artificially generated microbial
community containing P. gingivalis, Aggregatibacter actinomycetemcomitans and
Peptostreptococcus micros. The specificity of the P. gingivalis IgG–SMAP28 conjugate in this
mixed culture was concentration-dependent. The conjugate at 50 μg protein/mL lacked specificity
and killed P. gingivalis, A. actinomycetemcomitans and P. micros. The conjugate at 20 μg protein/
mL was more specific and killed P. gingivalis. This is an initial step to develop a selective
antimicrobial agent that can eliminate a specific periodontal pathogen, such as P. gingivalis, from
patients with periodontal disease without harming the normal commensal flora.
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Antibiotics have the proven capacity to inhibit or kill microorganisms and thus are
successfully used to treat many bacterial diseases in animals and humans [1,2].
Unfortunately, there are some problems. First, the widespread, indiscriminate or excessive
use of many common antibiotics is thought to lead to the development of drug-resistant
bacteria [2–4]. Second, antibiotic use in some individuals can result in a variety of ill effects
[5]. Nausea, vomiting, abdominal discomfort, diarrhoea, allergic skin rashes and drug fever
are induced by the penicillins, cephalosporins and other-related β-lactam antibiotics.
Neurotoxicity, nephrotoxicity and vestibular toxicity are induced by the aminoglycosides.
Infusion-site phlebitis is induced by the glycopeptides, and bone marrow toxicity is induced
by chloramphenicol [5,6]. Finally, normal commensal flora are also susceptible to killing by
antibiotics. Reduction in the types of bacteria and their concentrations leads to secondary
Candida albicans infections on mucosal surfaces or to Clostridium difficile infections in the
gastrointestinal tract [6].
Both local and systemic antibiotic therapy is used to treat periodontal disease [7,8].
Systemically administered antibiotics provide a clear clinical benefit; periodontal attachment
levels are much better in patients post therapy compared with patients not receiving these
agents [9,10]. Combined with non-surgical and surgical treatment, antibiotics also reduce
the number of periodontal pathogens. However, many of the above described side effects
still occur. Therefore, there is a need to develop a more ‘organism-specific’ targeted
approach that kills specific periodontal pathogenic bacteria in complex polymicrobial
environments, yet does not alter the composition or concentration of the normal commensal
flora.
Antimicrobial peptides represent a new class of antibiotics that rapidly lyse or inhibit
susceptible bacteria, are easy to synthesise in large quantities, work in synergy with other
antimicrobial agents, and have very few side effects [11–13]. Because their antimicrobial
activity is fast and their minimal inhibitory concentrations (MICs) are low for many
susceptible bacteria, it is thought that antimicrobial peptides generally do not induce
bacterial resistance [14]. However, some bacteria have proteolytic enzymes, positively
charged moieties linked to teichoic acids, and positively charged moieties linked to
lipopolysaccharides that allow them to resist the antimicrobial activity of these peptides [15–
18]. Recently, Perron et al. [19] induced experimental resistance in Escherichia coli and
Pseudomonas fluorescens to pexiganan, an analogue of magainin. Therefore, indiscriminate
use of broad-spectrum antimicrobial peptides may not be prudent [19,20]. However, if
antimicrobial peptides were coupled to a ligand or receptor for a specific pathogenic
bacteria, they could be used at lower concentrations, would have narrow-spectrum or
‘targeted’ antimicrobial activity, and induce fewer side effects. Porphyromonas gingivalis,
which is generally thought to be resistant to human β-defensins [21] and some antimicrobial
peptides [22], may be a potential target.
In this study, sheep myeloid antimicrobial peptide (SMAP) 28 was linked to affinity- and
protein G-purified rabbit immunoglobulin G (IgG) antibodies specific to the outer surface of
P. gingivalis strain 381 (Fig. 1) and it was demonstrated that it could selectively kill P.
gingivalis in an artificially generated microbial community containing P. gingivalis,
Aggregatibacter actinomycetemcomitans and Peptostreptococcus micros. This approach is
an initial step for developing a selective antimicrobial agent capable of eliminating a specific
periodontal pathogen, such as P. gingivalis, from patients with periodontal disease without
harming the normal commensal flora.
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2. Materials and methods
2.1. Synthesis of SMAP28
SMAP28 (RGLRRLGRKIAHGVKKYGPTVLRIIRIA-(NH2)) was synthesised by
NeoMPS, Inc. (San Diego, CA) and suspended in 0.01 M sodium phosphate buffer (pH 7.2)
with 145 mM NaCl (0.01 M phosphate-buffered saline (PBS) (pH 7.2)). Its purity was
confirmed by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry
(MALDI-TOF-MS) (High Resolution Mass Spectrometry Facility, The University of Iowa,
Iowa City, IA) and reversed-phase high-performance liquid chromatography (HPLC).
2.2. Bacterial species and growth conditions
Porphyromonas gingivalis strain 381 (obtained from Ann Progulske-Fox, Department of
Oral Biology, University of Florida, Gainesville, FL), A. actinomycetemcomitans FDC-Y4
and P. micros were used. All three organisms were grown as previously described at 37 °C
in an atmosphere containing 85% N2, 10% H2 and 5% CO2 [23]. Porphyromonas gingivalis
strain 381 was grown in tryptic soy broth (Difco Laboratories, Detroit, MI) supplemented
with 5 μg/mL hemin (Sigma, St Louis, MO) and vitamin K (Sigma). Aggregatibacter
actinomycetemcomitans was grown in tryptic soy broth supplemented with 0.6% yeast
extract (Difco Laboratories). Peptostreptococcus micros was grown in brain–heart infusion
(Difco Laboratories) supplemented with 0.5% neopeptone and 5 μg/mL hemin.
2.3. Preparation of antiserum and isolation of P. gingivalis-specific IgG antibody
A water-in-oil emulsified, whole-cell bacterin was prepared. Each immunising 1 mL dose
contained 1.0 × 108 colony-forming units (CFU) of P. gingivalis strain 381 and 25 μg of
MDP in 140 mM NaCl with 0.3% formalin in a 50% oil emulsion of Freund’s incomplete
adjuvant. Two rabbits were immunised seven times over a 13-week period (IMGENEX
Corp., San Diego, CA). Pre-bleed serum samples were collected before immunisation and
antiserum samples were collected at 9, 11 and 13 weeks.
Rabbit IgG antibody to P. gingivalis cell surface antigens was isolated by affinity
chromatography using the Pierce AminoLink® Plus Immobilization Kit (Nos. 44894 and
20394; Pierce, Rockford, IL) to link formalin-fixed whole cells of P. gingivalis to the gel
matrix. The coupling efficiency was estimated to be 33.9% for P. gingivalis whole cells.
Porphyromonas gingivalis-specific IgG antibodies were isolated from the affinity column-
eluted fractions concentrated using a HiTrap Protein G HP Cartridge (No. 17-0405-01;
Pierce) and dialysed overnight against 0.01 M PBS (pH 7.2). Seven millilitres of 0.10 mg/
mL (total protein 0.7 mg) of affinity-purified P. gingivalis IgG antibody was obtained. IgG
isolated from pre-immune rabbit serum (IgGAb control) and IgG to P. gingivalis isolated
from immune rabbit serum (PgAb control) were used as control solutions.
2.4. Whole cell enzyme-linked immunosorbent assay (ELISA) analysis
A whole-cell ELISA was performed at 26 °C as described by Zagursky et al. [24]. Briefly, a
suspension of P. gingivalis in 140 mM NaCl with 0.3% formalin was adjusted to contain 1.0
× 108 CFU/mL in the spectrophotometer (0.108 optical density (O.D.) at 600 nm) and then
100 μL/well of this suspension was put into Immulon 1 microtitre wells and dried overnight.
Non-specific antibody binding sites were blocked with 0.01 M Tris buffer containing 0.145
M NaCl, 1.0% fish gelatin and 0.05% blocking buffer and then two-fold dilutions of rabbit
antiserum were added. After 60 min, all wells were washed twice with blocking buffer and
bound rabbit IgG was detected with peroxidase-labelled goat anti-rabbit IgG antibody (1 μg/
mL) (No. 074-1506; KPL, Inc., Gaithersburg, MD) using tetramethylbenzidine (TMB)
peroxidase developing reagent (No. 50-85-05; KPL, Inc.) and TMB stop reagent (No.
50-85-05; KPL, Inc.). The O.D. values of the wells in the plate were determined at 450 nm
Franzman et al. Page 3













(PowerWaveX; Bio-Tek Instruments, Inc., Winooski, VT) and values of the blank wells
were subtracted from the test values. Linear regression of the log2 of dilution (x-axis) was
plotted against the O.D. of the dilution (y-axis) to determine the slope of the line. Antibody
titre was calculated as the log2 dilution value at the 0.1 O.D. intercept [25].
2.5. SMAP28 and IgG conjugation
SMAP28 was conjugated to affinity-purified IgG antibody using the Controlled Protein–
Protein Cross-Linking Kit (No. 23456; Pierce) as outlined in Fig. 1. This kit uses maleimide
to link the amine groups of SMAP28 to the sulfhydryl groups of the IgG antibody. SMAP28
contains 11 free amine groups, of which 4 are available for linker attachment, 1 at each
lysine or arginine residue.
SMAP28 (1.0 mg/mL of 0.01 M PBS (pH 7.2)) was mixed with Sulfo-SMCC and incubated
for 30 min at 26 °C. Unreacted maleimide reagents were removed using a Dextran Desalting
Column. Peptide concentrations in eluted fractions were determined and those containing
SMAP28 with maleimide linkers were pooled. MALDI-TOF-MS was used to confirm that
maleimide linkers attached to SMAP28 (Fig. 2).
Two options (IIA and IIB) were used to prepare sulfhydryl-modified IgG antibody. In option
IIA, the IgG antibody was suspended in 0.01 M PBS (pH 7.2), mixed with the kit
conjugation/activation buffer and activated kit immobilised-reductant and incubated for 60
min at 37 °C. The mixture was centrifuged to pellet the kit immobilised-reductant. The
supernatant contained the sulfhydryl-modified IgG antibody for the protein–protein cross-
linking procedure with the SMAP28 with maleimide linkers.
In option IIB, sulfhydryl groups were artificially added by reaction with N-succinimidyl-S-
acetylthioacetate (SATA). The IgG antibody was suspended in 0.01 M PBS (pH 7.2) (1.0
mL) and a 10 molar excess of SATA solution (SATA/dimethylformamide) was added and
incubated for 20 min at 26 °C. Then, 100 μL of hydroxylamine HCl solution was added to
the SATA-modified IgG antibody and the mixture was incubated for 120 min at 26 °C.
Unbound reagents were removed by passing the de-protected sulfhydryl-IgG antibody
solution over a desalting column. PBS–ethylene diamine tetra-acetic acid (EDTA) was used
to elute sulfhydryl-IgG antibody and 1.0 mL fractions were collected. Protein concentrations
were determined at A280 and fractions containing most of the sulfhydryl-IgG antibody were
pooled. SMAP28 with maleimide linkers and sulfhydryl-IgG antibody were mixed in
approximately equal molar amounts and incubated for 60 min at 26 °C.
Preliminary work showed that conjugation by option IIB was more effective and a P.
gingivalis IgG–SMAP28 conjugate developed this way was more specific to P. gingivalis.
Thereafter, the conjugate was prepared using option IIB and was called the P. gingivalis
IgG–SMAP28 conjugate.
2.6. HPLC
SMAP28 and the SMAP28 with maleimide linkers were separated on an Acclaim 300, C18,
3 μm analytical column (Dionex Corp., San Francisco, CA) using a Summit HPLC system
(Dionex) with Chromeleon software and eluted with a gradient of acetonitrile (0–100%) in
0.1% trifluoroacetic acid. Fractions were collected in a FC 144 fraction collector, pooled
with similar fractions of previous runs and dried overnight by rotary evaporation under
vacuum at room temperature.
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A dot-blot assay was used to confirm the presence both of the affinity-purified rabbit IgG
antibody and of SMAP28 in the P. gingivalis IgG–SMAP28 conjugate. Briefly, 1.0 μL of
the P. gingivalis IgG–SMAP28 conjugate and P. gingivalis IgG were placed on Immobilon-
P transfer membranes, allowed to dry and soaked overnight at 26 °C in blocking buffer.
Rabbit IgG antibody in the P. gingivalis IgG–SMAP28 conjugate was detected with
peroxidase-labelled goat anti-rabbit antibody (1.0 μg/mL) (No. 074-1506; KPL, Inc.) using
CN peroxidase developing reagent (No. 50-73-014; KPL, Inc.). SMAP28 in the P. gingivalis
IgG–SMAP28 conjugate was detected first using goat anti-SMAP28 antibody (1:20 dilution;
courtesy of Brian Tack) [25] and then peroxidase-labelled rabbit anti-goat antibody (1.0 μg/
mL) (No. 14-13-06, KPL, Inc.) using 4CN peroxidase developing reagent (No. 50-73-01;
KPL, Inc.).
2.8. Radial diffusion antimicrobial assay
The MICs of SMAP28 and SMAP28 with maleimide linkers were determined by the radial
diffusion assay as previously described in our laboratory [23,26,27]. After incubation for
24–48 h, zones of inhibition were recorded with a Boley gauge as radial diffusion units
(zone of inhibition–well diameter × 10). The x-intercept was obtained from the relationship
between radial diffusion units versus log10 peptide concentration as determined after
regression [23].
2.9. Porphyromonas gingivalis IgG–SMAP28 conjugate-specific killing in a mixed culture
suspension
The specificity and activity of the P. gingivalis IgG–SMAP28 conjugate was determined in
an artificially generated microbial community containing P. micros, A.
actinomycetemcomitans and P. gingivalis. These organisms were grown for 48 h in their
respective media at 37 °C under anaerobic conditions and diluted in reduced saline to a
density containing ca. 1 × 108 CFU/mL (0.108 O.D. at 600 nm) (Spectronic 20D+; Thermo
Fisher Scientific, Inc., Waltham, MA). Each culture was diluted 10-fold to contain 104 CFU/
mL. Then, 2.0, 0.25 and 2.0 mL of P. gingivalis, A. actinomycetemcomitans and P. micros,
respectively, was added to 5.75 mL of reduced anaerobic saline (e.g. constituting the 10−5
dilution of each) and diluted two-fold with the P. gingivalis IgG–SMAP28 conjugate and
two control solutions, IgGAb control and PgAb control. At 0, 10, 20 and 30 min, 100 μL
was removed and plated onto anaerobic blood agar (CDC formulation; Remel, Lenexa, KS)
and incubated at 37 °C. After 9 days, bacterial colonies of differing morphologies, sizes and
colour were counted by three different observers.
2.10. Statistical analyses
The experiment was divided into treatments at different time points: P. gingivalis IgG–
SMAP28 conjugate, P. gingivalis antibody control (PgAb control) and pre-immune IgG
antibody control (IgGAb control) at 0, 10, 20 and 30 min, defining 12 total treatments for
the study. Each treatment had three plates and the experiments were performed on two
different days using two different freshly prepared conjugates. Since day-to-day differences
could affect the assays, each day was considered a block.
A multifactorial analysis of variance (ANOVA) model was used to analyse the effect of
treatments, time and day on the number of CFU as well as to assess two- and three-way
interactions. Logarithm transformations of the form log10 (CFU+1) were used as needed to
conform to model assumptions such as normality and homoscedasticity. Adjustments for
multiple comparisons utilised Tukey’s studentized range.
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3.1. Antimicrobial activity of SMAP28 and SMAP28 with maleimide linkers
MALDI-TOF-MS showed that up to four maleimide linkers were attached to SMAP28,
likely at available lysine or arginine residues (Fig. 2). When separated by HPLC, the linker
solution contained four broad peaks that eluted at 13.5 min (fraction 14), 14.3 min (fraction
15), 14.8 min (fraction 15) and 15.6 min (fraction 16).
Fraction 15 contained masses 3199.64, 3418.32 and 3637.90 m/z corresponding to
SMAP28, SMAP28 with one maleimide linker, and SMAP28 with two maleimide linkers,
respectively. Fraction 16 contained masses 3419.65, 3638.87 and 3860.11 m/z
corresponding to SMAP28 with one maleimide linker, SMAP28 with two maleimide linkers,
and SMAP28 with three maleimide linkers, respectively. In other runs, fraction 17 contained
masses 3419.35, 3637.90 and 3860.03 m/z corresponding to SMAP28 with one maleimide
linker, SMAP28 with two maleimide linkers, and SMAP28 with three maleimide linkers,
respectively (not shown).
The antimicrobial activities of SMAP28 and SMAP28 with maleimide linkers were nearly
identical, suggesting that the presence of the linkers did not affect antimicrobial activity. The
MICs for native SMAP28 were 3.9, 5.9 and 5.0 μg/mL for E. coli ATCC 12795,
Pseudomonas aeruginosa ATCC 47085 and Staphylococcus aureus ATCC 29213,
respectively. The MICs for SMAP28 with maleimide linkers solution were 4.7, 4.7 and 4.4
μg/mL for E. coli, P. aeruginosa and S. aureus, respectively.
3.2. Antimicrobial activity of the P. gingivalis IgG–SMAP28 conjugate
The effect of treatment with P. gingivalis IgG–SMAP28 conjugate, PgAb control or IgGAb
control on the viability of P. gingivalis, A. actinomycetemcomitans and P. micros was
assessed over four time periods. The P. gingivalis IgG–SMAP28 conjugate at 50 μg/mL
final protein lacked specificity and killed P. gingivalis, A. actinomycetemcomitans and P.
micros. The conjugate at 20 μg/mL final protein was more specific and the viability of P.
gingivalis dropped at a faster rate than that of A. actinomycetemcomitans and P. micros
(Table 1; Fig. 3).
For P. gingivalis, the P. gingivalis IgG–SMAP28 conjugate was active and there was a
significant negative correlation with time in both experiments (P = 0.0001) (Table 1; Fig. 3).
A significant negative correlation with time (P = 0.04) was also seen for P. gingivalis
incubated in IgGAb control (Table 1). For P. gingivalis, there was a significant interaction
between treatments and time (P < 0.0001). The treatment mean curves (Fig. 3) for the four
time levels support this conclusion. The number of P. gingivalis CFU declined over time
under all three treatments, but this relationship with time was significant under some
treatments and not under others (Table 1).
Table 1 also lists the Spearman rank correlation coefficient (ρ) for this bacteria by treatment.
Treatment with P. gingivalis IgG–SMAP28 conjugate showed a significant negative
correlation with time (ρ = −0.72; P = 0.0001) and, similarly, the IgGAb control
demonstrated a negative correlation with time (ρ = −0.42; P = 0.04). Using a simple linear
regression line, the average rate of decline over time was estimated and is listed in Table 1.
The average decline in the number of CFU for every 10 min for P. gingivalis was 430 (P.
gingivalis IgG–SMAP28 conjugate), 15 (PgAb control) and 210 (IgGAb control).
For A. actinomycetemcomitans, the nature of time and treatment effects was not entirely
consistent. The interaction between treatment and time was not significant (P = 0.61) in the
first experimental replication but the interaction was significant (P = 0.0019) when run in
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the second experimental replication. The data for the first experimental replication did not
show that time was a significant factor (P = 0.85) whilst treatment was significant (P =
0.02).
Tukey’s studentized range test demonstrated that treatment with the conjugate and the
IgGAb control were significantly different. When the data were combined for the 2 days, the
interaction between treatment and time became insignificant (P = 0.15). The Tukey’s
studentized range test for the combined data indicated that all the pairwise comparisons
between treatments were significant at the 5% level. The interaction between treatment, time
and the day of the experiment for A. actinomycetemcomitans was not statistically significant
(P = 0.09). Figures 3–5 shows the treatment mean curves for this bacterium.
For P. micros, the interaction between time and treatment was not statistically significant (P
= 0.22) in the first experimental replication but it was significant (P = 0.003) in the second
experimental replication. The treatment mean curves for P. micros are shown in Figs 3–5.
When the data for the 2 days were combined and analysed, the interaction between time and
treatment became non-significant (P = 0.07), whilst both time and treatment were significant
factors in the CFU. The three-way interaction between time, treatment and the day
experiments were performed was not significant (P = 0.51).
Tukey’s studentized range test shows a significant difference (at the 5% level) between
treatment with IgGAb control, P. gingivalis IgG–SMAP28 conjugate and PgAb control.
Treatments with P. gingivalis IgG–SMAP28 conjugate and PgAb control were not
significantly different at the 5% level. Peptostreptococcus micros showed a decline in
bacterial counts over time for all four treatments (Figs 3–5). The Spearman correlation
coefficient ρ (for P. micros) is listed in Table 1. The P. micros count in the IgGAb control (ρ
= −0.42; P = 0.04) and PgAb control (ρ = −0.089; P = 0.0001) showed a significant
negative correlation with time but this negative correlation was not significant for P. micros
in the P. gingivalis IgG–SMAP28 conjugate (ρ = −0.35; P = 0.095). Using a simple linear
regression line, the estimate of average rate of decline in CFU over time was evaluated and
is listed in Table 1. This rate of decline for every 10 min is 102 (P. gingivalis IgG–SMAP28
conjugate), 83 (PgAb control) and 470 (IgGAb control).
4. Discussion
SMAP28 was conjugated to an IgG antibody specific to the outer surface of P. gingivalis via
a maleimide linker. When added to an artificially generated microbial community containing
P. gingivalis, A. actinomycetemcomitans and P. micros, the antimicrobial activity of the P.
gingivalis IgG–SMAP28 conjugate for P. gingivalis was dependent upon the conjugation
procedure and the concentration of the conjugate. At 50 μg/mL final protein, the conjugate
lacked specificity and rapidly killed all three bacteria. At 20 μg/mL final protein, the
conjugate was more specific and killed P. gingivalis. The two-factor ANOVA showed a
strong interaction between treatment, time and experiment for all three bacteria.
Antimicrobial peptides can be directed to the surface of select microorganisms. This
delivery system works well and has been used by other investigators. Peschen et al. [28]
used a Fusarium spp.-specific antibody linked to antifungal peptides to protect plants against
a Fusarium oxysporum f.sp. matthiolae infection. Qiu et al. [29] used a staphylococcal
AgrD1 pheromone linked with the channel-forming domain of colicin Ia to kill meticillin-
sensitive and -resistant S. aureus, but not Staphylococcus epidermidis or Streptococcus
pneumoniae. Similarly, Qiu et al. [30] used an enterococcal cCF109 pheromone fused with
the channel-forming domain of colicin Ia to kill vancomycin-resistant Enterococcus faecalis.
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Vancomycin-resistant E. faecalis-infected mice survived when treated with this peptide, but
untreated control mice did not survive [30].
Although the concept in this study is feasible, additional work is needed (a) to reduce the
variability in the antimicrobial activity of the conjugate, (b) to identify other carriers and (c)
to define the mechanism of antimicrobial activity. For example, we observed variability in
attaching both the maleimide linker and P. gingivalis IgG antibody to SMAP28 that likely
induced some experiment-to-experiment variability in the antimicrobial activity of the
conjugate seen in Figs 3–5. Furthermore, we could not determine the number of SMAP28
peptides bound to the P. gingivalis-specific antibodies nor their binding locations. It is likely
that they did not bind to the Fab binding sites.
Other carriers may be more reliable. Future work will focus on identifying other carrier
proteins as well as refining the specificity of the carrier peptide–SMAP28 conjugate for P.
gingivalis. Besides antibodies, ligands could include fragments of hemin [31], peptides of
proline-rich protein 1 [32–34], portions of Streptococcus gordonii SspB [35], fragments of
glycoproteins [36] or fragment of lactoferrin [37].
SMAP29 has a disordered structure in aqueous buffers but has significant helicity in
membrane-like environments, including sodium dodecyl sulphate (SDS) micelles,
lipopolysaccharide dispersions and trifluoroethanol buffer systems [38]. A structure
determined by nuclear magnetic resonance (NMR) indicated that residues 8–17 are helical,
residues 18–19 form a hinge and residues 20–28 form an ordered hydrophobic segment. We
do not know whether attachment of linkers or proteins to SMAP28 would alter its helical
structure or impair its ability to insert into microbial membranes. It is likely the maleimide
linkers are attached to lysine or arginine residues on the hydrophilic face of the SMAP28 α
helix. IgG, linked to the hydrophilic face via maleimide, would likely allow the peptide to
still form an α helix and insert into the bacterial membrane. Characterising the peptide
antimicrobial activity with and without the linked P. gingivalis-specific IgG antibody will
give insight on how to reduce the broad-spectrum antimicrobial activity of this conjugate at
higher concentrations and increase the specific targeted pathogen antimicrobial activity in a
mixed microbial culture.
In summary, SMAP28 linked to affinity- and protein G-purified rabbit IgG antibodies could
selectively kill P. gingivalis in an artificially generated microbial community. This approach
is an initial step for developing a selective antimicrobial reagent that could be used to
eliminate specific periodontal pathogens, such as P. gingivalis, from patients with
periodontal disease without harming their normal commensal population.
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An overview of the procedure used to prepare the Porphyromonas gingivalis IgG-SMAP28
conjugate. Antiserum to whole cells of P. gingivalis was prepared in rabbits. Specific cell
surface antibodies were then isolated with an immunoaffinity column and specific IgG was
isolated using a protein G column. SMAP28 was then synthesised and a maleimide linker
was attached. SMAP28 with the maleimide linker was attached to the specific P. gingivalis
IgG antibody and dialysed. The conjugate was then tested for specific antimicrobial activity.
IgG, immunoglobulin G; SMAP28, sheep myeloid antimicrobial peptide 28.
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Matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF-
MS) showing that the maleimide linkers were successfully attached to sheep myeloid
antimicrobial peptide (SMAP) 28. Up to four distinct peaks were seen. Each peak
corresponded to the molecular mass of SMAP28 (i.e. 3198.95 Da) and the number of
maleimide linkers attached (i.e. 219.24 Da). Predicted masses were 3418.19 Da (SMAP28
with one maleimide linker), 3637.43 Da (SMAP28 with two maleimide linkers), 3856.67 Da
(SMAP28 with three maleimide linkers) and 4075.91 Da (SMAP28 with four maleimide
linkers). Distinct peaks were seen at 3419.54, 3638.75, 3857.80 and 4077.32 m/z. Proteins
with masses of 2867.81 Da and 5734.61 Da were used as internal calibration standards.
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Porphyromonas gingivalis IgG–SMAP28 conjugate-mediated killing of P. gingivalis in an
artificially generated microbial community containing Aggregatibacter
actinomycetemcomitans and Peptostreptococcus micros. (a,b) Two separate experiments
show the decline of P. gingivalis after incubation with the conjugate. (c) At 30 min there
was a clear reduction of small black P. gingivalis colonies. Colonies of A.
actinomycetemcomitans and P. micros are still visible. The final concentration of conjugate
protein was 20 μg/mL. IgG, immunoglobulin G; SMAP28, sheep myeloid antimicrobial
peptide 28. CFU, colony-forming units.
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Viability of Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans and
Peptostreptococcus micros incubated in the P. gingivalis immunoglobulin G (IgG) antibody
control solution. The final concentration of protein was 20 μg/mL. CFU, colony-forming
units.
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Viability of Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans and
Peptostreptococcus micros incubated in the immunoglobulin G (IgG) antibody isolated from
pre-immune serum. (a) In one experiment, the viability P. gingivalis and P. micros declined
over the 30-min period, whereas the viability of A. actinomycetemcomitans did not. (b) In
another experiment the bacterial concentrations of all three were increased. The viability of
P. micros declined over the 30-min period, whereas the viability of P. gingivalis and A.
actinomycetemcomitans did not. The final concentration of protein was 20 μg/mL. CFU,
colony-forming units.
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